Traders Purchase Large Volume of Illumina Call Options (NASDAQ:ILMN)

Illumina, Inc. (NASDAQ:ILMN - Get Free Report) was the recipient of unusually large options trading activity on Tuesday. Stock investors acquired 6,429 call options on the company. This represents an increase of approximately 67% compared to the typical volume of 3,845 call options.

Insider Buying and Selling

In related news, CFO Ankur Dhingra bought 6,100 shares of the company's stock in a transaction that occurred on Monday, May 12th. The stock was purchased at an average price of $81.21 per share, for a total transaction of $495,381.00. Following the completion of the transaction, the chief financial officer now owns 24,906 shares in the company, valued at $2,022,616.26. The trade was a 32.44% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. 2.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. Rise Advisors LLC grew its position in shares of Illumina by 173.6% in the 1st quarter. Rise Advisors LLC now owns 353 shares of the life sciences company's stock worth $28,000 after buying an additional 224 shares during the last quarter. Rakuten Securities Inc. grew its position in shares of Illumina by 290.3% in the 1st quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company's stock worth $29,000 after buying an additional 270 shares during the last quarter. Golden State Wealth Management LLC purchased a new position in shares of Illumina in the 4th quarter worth approximately $32,000. Center for Financial Planning Inc. purchased a new position in shares of Illumina in the 1st quarter worth approximately $33,000. Finally, Fourth Dimension Wealth LLC acquired a new stake in Illumina in the 4th quarter worth approximately $40,000. Hedge funds and other institutional investors own 89.42% of the company's stock.

Illumina Stock Down 1.4%

NASDAQ ILMN traded down $1.20 during trading on Friday, reaching $86.93. 1,612,726 shares of the company's stock traded hands, compared to its average volume of 2,279,790. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. The firm has a market cap of $13.76 billion, a price-to-earnings ratio of -11.32, a price-to-earnings-growth ratio of 1.60 and a beta of 1.32. The company's 50 day simple moving average is $79.08 and its two-hundred day simple moving average is $102.92. Illumina has a 12-month low of $68.70 and a 12-month high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its earnings results on Thursday, May 8th. The life sciences company reported $0.97 EPS for the quarter, beating analysts' consensus estimates of $0.96 by $0.01. The business had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $1.03 billion. Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. The company's revenue for the quarter was down 1.4% on a year-over-year basis. During the same quarter last year, the firm posted $0.98 EPS. As a group, sell-side analysts forecast that Illumina will post 4.51 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Barclays dropped their target price on shares of Illumina from $100.00 to $77.00 and set an "underweight" rating for the company in a research report on Thursday, April 10th. Stephens restated an "overweight" rating and set a $105.00 target price on shares of Illumina in a research report on Tuesday, May 20th. Guggenheim dropped their price objective on shares of Illumina from $122.00 to $114.00 and set a "buy" rating for the company in a research note on Friday, May 9th. Canaccord Genuity Group lifted their price objective on shares of Illumina from $87.00 to $99.00 and gave the stock a "hold" rating in a research note on Wednesday. Finally, Royal Bank of Canada dropped their price objective on shares of Illumina from $128.00 to $112.00 and set an "outperform" rating for the company in a research note on Tuesday, April 8th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $126.94.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.